Nyxoah (NasdaqGM:NYXH) 2025 Conference Transcript

Summary of Nyxoah Conference Call Company Overview - Company: Nyxoah - Industry: Hypoglossal Nerve Stimulation (HG&S) for Obstructive Sleep Apnea (OSA) Key Points Commercial Launch and Structure - Nyxoah launched its Genio device on August 11, with a focus on high-volume accounts in the U.S. market [3][6] - Currently, there are approximately 1,500 implanting accounts, with 400 accounts generating 75% of the volume [3][11] - The commercial team consists of 25 territory managers targeting 125 high-volume accounts, with plans to add 75 new accounts each quarter [6][11] - The strategy emphasizes quality over quantity, focusing on high-volume centers of excellence [11][12] Training and Surgeons - As of now, 121 surgeons have been trained across the 125 targeted accounts, indicating strong momentum [17][18] - Feedback from surgeons highlights the optionality and clinical differentiation of Genio compared to existing treatments [18][24] Patient Identification and Demand - The target patient demographic includes those who prefer not to have a battery implanted and those with positional OSA [23][24] - There is a noted pre-existing demand for Genio among patients who previously opted out of traditional implants [25][26] Surgical Proficiency and Time - The average surgical time has decreased from 90 minutes for initial procedures to around 60 minutes as surgeons gain experience [29][30] - The fastest recorded implant was completed in 32 minutes by an experienced surgeon [30] Reimbursement and Payer Relationships - All reimbursement submissions to Medicare and private payers have been approved, with no rejections reported [32][33] - Major payers like Blue Cross Blue Shield and UnitedHealth have accepted the reimbursement code for Genio [32][34] Financial Strategy and Funding - The company is focusing investments on U.S. commercial launch and innovation while managing cash burn effectively [41][42] - Plans to raise capital to support four to five quarters of commercial success are in place [42] Future Opportunities and Trials - The Axis trial for the triple C indication has stopped enrollment, with potential label approval expected by late 2026 or early 2027 [45][46] - Nyxoah aims to differentiate itself from competitors by focusing on innovative platforms rather than traditional pacemaker solutions [47][48] GLP-1 Impact - The introduction of GLP-1 medications is seen as a positive development, potentially increasing the patient pool for OSA treatments [60][63] - Nyxoah's strategy focuses on managing chronic diseases and improving patient outcomes through innovative solutions [61][63] Next Generation Technology - Future developments aim to eliminate wearable components, incorporating self-learning systems for patient convenience [67][68] - By 2030, Nyxoah expects to offer devices without any wearable components, enhancing user experience [68] Additional Insights - The company emphasizes the importance of patient management and setting correct expectations for treatment outcomes [59][61] - Nyxoah's approach to OSA treatment is positioned as a long-term chronic disease management strategy, focusing on patient ownership and compliance [48][61]